...
首页> 外文期刊>Medicine. >A novel immunogenomic prognostic signature in lung squamous carcinoma
【24h】

A novel immunogenomic prognostic signature in lung squamous carcinoma

机译:肺鳞状癌中的一种新型免疫原性预后签名

获取原文

摘要

ABSTRACT:Lung squamous carcinoma (LUSC) is a common subtype of lung cancer with limited available therapy and is thus associated with poor survival. Immune infiltrating cells and immune-related genes (IRGs) play a key role in the clinical outcomes of LUSC. In the present study, we aimed to develop a potential immunogenomic prognostic signature for patients with LUSC. The transcriptional profiles of 501 LUSC samples from The Cancer Genome Atlas (TCGA) and 2498 IRGs from the ImmPort database were used to develop the signature by Cox regression analysis. Ten differentially expressed and survival-associated IRGs were used to develop the risk signature, which could serve as an independent prognostic and predictive factor for patients with LUSC. Furthermore, this risk signature correlated with overall survival and clinical features, including age, in patients with LUSC. In addition, we identified 25 transcription factors that may regulate 15 survival-associated IRGs, using a regulatory network. Collectively, this immunogenomic signature could be a robust prognostic tool for patients with LUSC and holds great promise as individualized immunotherapy for LUSC.Copyright ? 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
机译:摘要:肺鳞状癌(LUSC)是肺癌的常见亚型,其可用治疗有限,因此与存活率差有关。免疫浸润细胞和免疫相关基因(IRGS)在LUSC的临床结果中发挥着关键作用。在本研究中,我们旨在为LUSC患者发育潜在的免疫原性预后签名。从Immport数据库中,来自癌症基因组Atlas(TCGA)和2498个IRGS的501个LUSC样品的转录谱用于通过COX回归分析来开发签名。 10次​​差异表达和生存相关的IRG用于发展风险签名,这可以作为LUSC患者的独立预测和预测因素。此外,这种风险符号与LUSC患者的整体存活和临床特征相关,包括年龄,包括年龄。此外,我们确定了25个转录因子,可以使用监管网络调节15个生存相关的IRG。统称,这种免疫因子签名可能是LUSC患者的强大预后工具,并使LUSC.COPYRIGHT作为个体化免疫疗法的许多希望? 2021提交人。由Wolters Kluwer Health,Inc。出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号